Inhibitors of the PD-1 Pathway in Tumor Therapy [TRANSLATING IMMUNOLOGY]
La; Fleur, M. W., Muroyama, Y., Drake, C. G., Sharpe, A. H.
The American Association of Immunologists (AAI)
Published 2018
The American Association of Immunologists (AAI)
Published 2018
| Publication Date: |
2018-01-09
|
|---|---|
| Publisher: |
The American Association of Immunologists (AAI)
|
| Print ISSN: |
0022-1767
|
| Electronic ISSN: |
1550-6606
|
| Topics: |
Medicine
|
| Published by: |
| _version_ | 1836398741375942656 |
|---|---|
| autor | La; Fleur, M. W., Muroyama, Y., Drake, C. G., Sharpe, A. H. |
| beschreibung | The programmed death 1 (PD-1) pathway delivers inhibitory signals that function as a brake for immune responses. This pathway limits the initiation and duration of immune responses, thereby protecting tissues from immune-mediated damage and autoimmune diseases. However, the PD-1 pathway also inhibits immune responses to tumors. The critical role of PD-1 in preventing antitumor immunity is demonstrated by the transformative effects of PD-1 pathway blockade in a broad range of cancers with the hallmark of durability of response. Despite this success, most patients do not respond to PD-1 monotherapy, and some patients experience adverse events. In this review, we discuss the functions of the PD-1 pathway and its translation to cancer immunotherapy. We also consider current challenges and opportunities for PD-1 cancer immunotherapy, including mechanisms of response and resistance, identification of biomarkers of response to PD-1 therapy, characterization and treatment of PD-1 therapy–related adverse events, and development of safe and effective combination therapies. |
| citation_standardnr | 6134031 |
| datenlieferant | ipn_articles |
| feed_id | 333 |
| feed_publisher | The American Association of Immunologists (AAI) |
| feed_publisher_url | http://www.aai.org/ |
| insertion_date | 2018-01-09 |
| journaleissn | 1550-6606 |
| journalissn | 0022-1767 |
| publikationsjahr_anzeige | 2018 |
| publikationsjahr_facette | 2018 |
| publikationsjahr_intervall | 7984:2015-2019 |
| publikationsjahr_sort | 2018 |
| publisher | The American Association of Immunologists (AAI) |
| quelle | Journal of Immunology |
| relation | http://www.jimmunol.org/cgi/content/short/200/2/375?rss=1 |
| search_space | articles |
| shingle_author_1 | La; Fleur, M. W., Muroyama, Y., Drake, C. G., Sharpe, A. H. |
| shingle_author_2 | La; Fleur, M. W., Muroyama, Y., Drake, C. G., Sharpe, A. H. |
| shingle_author_3 | La; Fleur, M. W., Muroyama, Y., Drake, C. G., Sharpe, A. H. |
| shingle_author_4 | La; Fleur, M. W., Muroyama, Y., Drake, C. G., Sharpe, A. H. |
| shingle_catch_all_1 | Inhibitors of the PD-1 Pathway in Tumor Therapy [TRANSLATING IMMUNOLOGY] The programmed death 1 (PD-1) pathway delivers inhibitory signals that function as a brake for immune responses. This pathway limits the initiation and duration of immune responses, thereby protecting tissues from immune-mediated damage and autoimmune diseases. However, the PD-1 pathway also inhibits immune responses to tumors. The critical role of PD-1 in preventing antitumor immunity is demonstrated by the transformative effects of PD-1 pathway blockade in a broad range of cancers with the hallmark of durability of response. Despite this success, most patients do not respond to PD-1 monotherapy, and some patients experience adverse events. In this review, we discuss the functions of the PD-1 pathway and its translation to cancer immunotherapy. We also consider current challenges and opportunities for PD-1 cancer immunotherapy, including mechanisms of response and resistance, identification of biomarkers of response to PD-1 therapy, characterization and treatment of PD-1 therapy–related adverse events, and development of safe and effective combination therapies. La; Fleur, M. W., Muroyama, Y., Drake, C. G., Sharpe, A. H. The American Association of Immunologists (AAI) 0022-1767 00221767 1550-6606 15506606 |
| shingle_catch_all_2 | Inhibitors of the PD-1 Pathway in Tumor Therapy [TRANSLATING IMMUNOLOGY] The programmed death 1 (PD-1) pathway delivers inhibitory signals that function as a brake for immune responses. This pathway limits the initiation and duration of immune responses, thereby protecting tissues from immune-mediated damage and autoimmune diseases. However, the PD-1 pathway also inhibits immune responses to tumors. The critical role of PD-1 in preventing antitumor immunity is demonstrated by the transformative effects of PD-1 pathway blockade in a broad range of cancers with the hallmark of durability of response. Despite this success, most patients do not respond to PD-1 monotherapy, and some patients experience adverse events. In this review, we discuss the functions of the PD-1 pathway and its translation to cancer immunotherapy. We also consider current challenges and opportunities for PD-1 cancer immunotherapy, including mechanisms of response and resistance, identification of biomarkers of response to PD-1 therapy, characterization and treatment of PD-1 therapy–related adverse events, and development of safe and effective combination therapies. La; Fleur, M. W., Muroyama, Y., Drake, C. G., Sharpe, A. H. The American Association of Immunologists (AAI) 0022-1767 00221767 1550-6606 15506606 |
| shingle_catch_all_3 | Inhibitors of the PD-1 Pathway in Tumor Therapy [TRANSLATING IMMUNOLOGY] The programmed death 1 (PD-1) pathway delivers inhibitory signals that function as a brake for immune responses. This pathway limits the initiation and duration of immune responses, thereby protecting tissues from immune-mediated damage and autoimmune diseases. However, the PD-1 pathway also inhibits immune responses to tumors. The critical role of PD-1 in preventing antitumor immunity is demonstrated by the transformative effects of PD-1 pathway blockade in a broad range of cancers with the hallmark of durability of response. Despite this success, most patients do not respond to PD-1 monotherapy, and some patients experience adverse events. In this review, we discuss the functions of the PD-1 pathway and its translation to cancer immunotherapy. We also consider current challenges and opportunities for PD-1 cancer immunotherapy, including mechanisms of response and resistance, identification of biomarkers of response to PD-1 therapy, characterization and treatment of PD-1 therapy–related adverse events, and development of safe and effective combination therapies. La; Fleur, M. W., Muroyama, Y., Drake, C. G., Sharpe, A. H. The American Association of Immunologists (AAI) 0022-1767 00221767 1550-6606 15506606 |
| shingle_catch_all_4 | Inhibitors of the PD-1 Pathway in Tumor Therapy [TRANSLATING IMMUNOLOGY] The programmed death 1 (PD-1) pathway delivers inhibitory signals that function as a brake for immune responses. This pathway limits the initiation and duration of immune responses, thereby protecting tissues from immune-mediated damage and autoimmune diseases. However, the PD-1 pathway also inhibits immune responses to tumors. The critical role of PD-1 in preventing antitumor immunity is demonstrated by the transformative effects of PD-1 pathway blockade in a broad range of cancers with the hallmark of durability of response. Despite this success, most patients do not respond to PD-1 monotherapy, and some patients experience adverse events. In this review, we discuss the functions of the PD-1 pathway and its translation to cancer immunotherapy. We also consider current challenges and opportunities for PD-1 cancer immunotherapy, including mechanisms of response and resistance, identification of biomarkers of response to PD-1 therapy, characterization and treatment of PD-1 therapy–related adverse events, and development of safe and effective combination therapies. La; Fleur, M. W., Muroyama, Y., Drake, C. G., Sharpe, A. H. The American Association of Immunologists (AAI) 0022-1767 00221767 1550-6606 15506606 |
| shingle_title_1 | Inhibitors of the PD-1 Pathway in Tumor Therapy [TRANSLATING IMMUNOLOGY] |
| shingle_title_2 | Inhibitors of the PD-1 Pathway in Tumor Therapy [TRANSLATING IMMUNOLOGY] |
| shingle_title_3 | Inhibitors of the PD-1 Pathway in Tumor Therapy [TRANSLATING IMMUNOLOGY] |
| shingle_title_4 | Inhibitors of the PD-1 Pathway in Tumor Therapy [TRANSLATING IMMUNOLOGY] |
| timestamp | 2025-06-30T23:31:53.781Z |
| titel | Inhibitors of the PD-1 Pathway in Tumor Therapy [TRANSLATING IMMUNOLOGY] |
| titel_suche | Inhibitors of the PD-1 Pathway in Tumor Therapy [TRANSLATING IMMUNOLOGY] |
| topic | WW-YZ |
| uid | ipn_articles_6134031 |